Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILIA phase 3 trial of tozorakimab in hospitalized adults with viral lung infection requiring oxygen
CTR20231511Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tozorakimab in Viral lower respiratory tract infection (VLRTI), sponsored by AstraZeneca. Started Jun 2023; status: active.
02
Drugs
tozorakimab
03
Conditions
Viral lower respiratory tract infection (VLRTI)
Beyond the preview
Go deeper on CTR20231511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231511.